Hypotension During Extracorporeal Circulatory Support Indicated for Cardiogenic Shock (RetroECMO-VP)

Vasoplegia During VA-ECMO for Refractory Cardiogenic Shock : Descriptive Analysis of a Retrospective Cohort

The cardiogenic shock is characterized by an alteration of organs function following a decrease in cardiac output linked to an impairment of cardiac performance. The prognosis remains poor with mortality between 40 and 50%. Nowadays, Extracorporeal Life Support (ECLS or VA-ECMO) is the referent therapy to restore blood flow in the body when medical treatment is not sufficient. Despite a good blood flow provided by the ECLS, many patients develop a severe hypotension (so called vasoplegia) due to a loss of vascular resistance mainly explained by the inflammatory response to shock and extracorporeal circulation. The treatment of this reaction includes vasopressors (Norepinephrine in usual care) and serum surrogate perfusion to achieve a mean arterial pressure (MAP) above 65 mmHg.

The purpose of this study is to describe the patients with vasoplegia among a retrospective cohort of patients treated with an ECLS in our university center, over the 4 last years, to determine major complication rate (including death, kidney failure and arrythmias) and their outcome. This study will provide consistent data useful for further trials about targets of pressure and treatments to increase blood pressure during ECLS.

Study Overview

• Status: Unknown
• Conditions: Hypotension; Vasoplegia; Extracorporeal Life Support
• Intervention / Treatment: Other: Arterial pressure management during circulatory support by VA-ECMO

Detailed Description

Cardiogenic shock is characterized by global tissue hypoperfusion following a decrease in cardiac output by impairing myocardial performance in the absence of hypovolemia. This life-threatening hypoperfusion quickly leads to multiple organs dysfunction with a high risk of cardiac arrest. The main cause is ischemic. The prognosis remains poor with mortality between 40 and 50% and depends on the speed of care by a specialized team. Early etiologic treatment is essential, but initial symptomatic management is based on catecholamines, mainly norepinephrine and dobutamine. The intra-aortic balloon pump showed no improvement in survival in large randomized studies. Refractory cardiogenic shock is defined by the inefficiency or intolerance of catecholamines and the indication of temporary circulatory support should be considered as soon as possible in the absence of contraindications (comorbidities, advanced age, therapeutic limitation). The veno-arterial extracorporeal membrane oxygenation (VA-ECMO or ECLS) is the preferred circulatory assistance in this indication because it provides an overall circulatory support up to 100% of the theoretical cardiac output, with oxygenation, and is quickly implanted peripherally (surgical or percutaneous cannulation of the femoral vein and the femoral artery). However, this extracorporeal circulation also has disadvantages by opposing a major afterload to the failing left ventricle and reducing or even abolishing the pulmonary circulation and blood flow in the heart chambers. In addition, the interaction with the artificial surfaces and the oxygenation membrane of the extracorporeal circuit contributes to the inflammatory response already initiated as a result of low cardiac output, tissue hypoperfusion, mesenteric ischemia and possibly myocardial infarction in case of acute coronary syndrome. This systemic inflammatory response syndrome (SIRS) is similar to sepsis and its main clinical presentation is a vascular dysfunction resulting in vasoplegia and capillary leak syndrome responsible for relative hypovolemia and interstitial inflation.

Since the flow provided by the centrifugal pump is continuous, the blood pressure under VA-ECMO presents low or no pulsatile waves and is better represented by the mean arterial pressure (MAP). The ideal targets of MAP under VA-ECMO are controversial but it is widely accepted that the MAP should not be less than 65mmHg as recommended in septic shock to maintain an acceptable perfusion pressure and should not exceed 95mmHg to limit afterload. Between these limits, the MAP must be individualized according to each situation (hypertensive patient for example). In France, Norepinephrine is the first-line drug to achieve this goal of MAP after correction of volemia, without dose limitation in the absence of currently validated alternative, while resistance mechanisms can be activated, and its efficiency may be limited in case of acidosis. Potential side effects are the occurrence of atrial or ventricular arrhythmias, tachycardia, pro-inflammatory cytokine release, immunosuppression, renal dysfunction.

Management of MAP and vasopressors under VA-ECMO is poorly described in the literature (5), although Norepinephrine is widely used in routine practice. In particular, the investigators do not know the frequency of use and Norepinephrine doses during ECMO-VA, as well as their prognostic involvement. Vasoplegia during VA-ECMO is defined by a Norepinephrine dose greater than 0.1µg/kg/min after a 500ml fluid challenge despite overall blood flow (ECMO + native heart) greater than 2l/min/m2 or allowing to achieve 65% of ScvO2.

This cohort study aims to describe the vasoplegia observed during VA-ECMO, the Norepinephrine treatment characteristics, complications and outcome. The primary end-point is the incidence of a composite criteria of major complications including death, acute kidney injury and arrythmias.

• Study Type: Observational
• Enrollment (Anticipated): 150

Contacts and Locations

• Study Contact: Name: Philippe Gaudard, MD; Phone Number: +33665849543; Email: p-gaudard@chu-montpellier.fr
• Study Contact Backup: Name: Helene David, MD; Phone Number: 33 629834346; Email: h-david@chu-montpellier.fr

Study Locations

• France
  • Montpellier, France, 34295
    • Recruiting
    • UH Montpellier
    • Contact: Philippe Gaudard, MD; Phone Number: +33665849543; Email: p-gaudard@chu-montpellier.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Patients admitted in intensive care unit for cardiogenic shock at the Montpellier University Hospital and who required a VA-ECMO implantation

Description

Inclusion criteria:

• Refractory cardiogenic shock due to an acute coronary syndrome, a decompensation of chronic heart failure, a infectious or adrenergic myocarditis, or in a post-cardiotomy setting
• Admitted in our intensive care unit between January 2015 and December 2018
• Vasoplegia during the first 48 hours of VA-ECMO requiring more than 0.1µg/kg/min of Norepinephrine continuous infusion

Exclusion criteria:

• Others etiologies of cardiogenic shock : heart transplant dysfunction, right ventricular failure after left ventricular assist device implantation, drug intoxication, hypothermia, pulmonary embolism
• Primary septic shock
• Cardiac arrest with a no-flow time greater than 5 min or a low-flow time greater than 45 min
• Opposition to participate after reception of the information letter

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Retrospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Vasoplegic ECMO; All patients during VA-ECMO support for cardiogenic shock who presented, within 48 hours after implantation, a vasoplegia defined by a norepinephrine dose greater than 0.1µg/kg/min after a 500ml fluid challenge despite overall blood flow (ECMO + native heart) greater than 2l/min/m2 or allowing to achieve 65% of ScvO2	Other: Arterial pressure management during circulatory support by VA-ECMO; Norepinephrine continuous infusion to maintain mean arterial pressure above 65 mmHg or at a higher level depending of the perfusion pressure targeted for the patient (mean arterial pressure between 65 and 85 mmHg)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Major complication composite criteria	Observation of acute kidney injury defined by KDIGO classification 2 or 3, or severe arrythmia (i.e. atrial fibrillation with heart rate above 150bpm or a mean arterial pressure decrease of at least 20%, sustained ventricular tachycardia, ventricular fibrillation), or death	Up to 7 days for acute kidney injury and arrythmia, and 30 days for death

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Initial refractory hypotension	Norepinephrine dose maintained always above 1µg/kg/min during the first 2 hours after VA-ECMO implantation for a minimal mean arterial pressure target at 65mmHg	Up to 2 hours
Refractory vasoplegia	Norepinephrine dose above 1µg/kg/min required to maintain mean arterial pressure above 65mmHg or at the personalized mean arterial pressure target	Up to 7 days
Mortality rate	Overall mortality rate	Through ICU discharge, an average of 1 month, up to 7, 30 and 90 days
VA-ECMO free days	Number of days alive free of VA-ECMO at 30 days after VA-ECMO implantation	At 30 days from the VA-ECMO implantation
Mean arterial pressure	lowest and highest mean arterial pressure (mmHg)	Up to 7 days
Pulse pressure	lowest and highest pulse pressure (mmHg) defined by the difference between systolic and diastolic pressure	Up to 7 days
Native cardiac output	lowest and highest cardiac output (L/min) measured by echocardiography (Doppler aortic Velocity Time Integration) or by a pulmonary artery catheter	Up to 7 days
ECMO flow	lowest and highest flow of VA-ECMO (L/min)	Up to 7 days
Lactate	Highest lactate level of the day (mmol/l)	Up to 7 days
ScvO2	Highest and lowest central venous oxygen saturation (%)	Up to 7 days
Urine output	Total urine output of the day (ml/24H)	Up to 7 days
Hydric balance	Total hydric balance calculated from day 0 to day 7 (ml)	Up to 7 days
Hospital stay	Length (days) of hospital stay from the VA-ECMO implantation before current care ward discharge (excluding rehabilitation time)	through study completion, an average of 3 month
Intensive care unit stay	Length (days) of intensive care unit stay from the VA-ECMO implantation	through study completion, an average of 3 month
Issue of VA-ECMO	Status after VA-ECMO including death, heart transplant, ventricular assist device, recovery, shock recurrence, therapy limitation	7 days after VA-ECMO withdrawal
Serious adverse events	Stroke, bleeding requiring blood transfusion or surgical revision, limb ischemia, mesenteric ischemia, documented infection	Trough VA-ECMO time completion, an average of 2 weeks
Organ failure assessment	Sequential Organ Failure Assessment score (0 to 24), higher values represent a worse outcome	At day 0, 5 and 10 after VA-ECMO implantation

Collaborators and Investigators

• Sponsor: University Hospital, Montpellier
• Investigators: Principal Investigator: Philippe Gaudard, MD, University Hospital, Montpellier

Publications and helpful links

General Publications

• van Diepen S, Katz JN, Albert NM, Henry TD, Jacobs AK, Kapur NK, Kilic A, Menon V, Ohman EM, Sweitzer NK, Thiele H, Washam JB, Cohen MG; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Mission: Lifeline. Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association. Circulation. 2017 Oct 17;136(16):e232-e268. doi: 10.1161/CIR.0000000000000525. Epub 2017 Sep 18.
• Tanaka D, Shimada S, Mullin M, Kreitler K, Cavarocchi N, Hirose H. What Is the Optimal Blood Pressure on Veno-Arterial Extracorporeal Membrane Oxygenation? Impact of Mean Arterial Pressure on Survival. ASAIO J. 2019 May/Jun;65(4):336-341. doi: 10.1097/MAT.0000000000000824.

Study record dates

Study Major Dates

• Study Start (Actual): June 30, 2019
• Primary Completion (Anticipated): December 1, 2020
• Study Completion (Anticipated): December 30, 2020

Study Registration Dates

• First Submitted: May 23, 2019
• First Submitted That Met QC Criteria: May 28, 2019
• First Posted (Actual): May 30, 2019

Study Record Updates

• Last Update Posted (Actual): March 10, 2020
• Last Update Submitted That Met QC Criteria: March 9, 2020
• Last Verified: March 1, 2020

More Information

Terms related to this study

• Keywords: Inflammatory response; Vasoplegia; Cardiogenic shock; Temporary circulatory support
• Additional Relevant MeSH Terms: Ischemia; Pathologic Processes; Necrosis; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Postoperative Complications; Shock; Myocardial Infarction; Infarction; Hypotension; Shock, Cardiogenic; Vasoplegia
• Other Study ID Numbers: RECHMPL19_0049

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No